

PARKINSON'S DISEASE IN THE ELDERLY

Dr Neo Xiumin Shermyn, Prof Tan Eng King

ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative disorder globally and its prevalence in Singapore is expected to increase exponentially with our ageing population. Diagnostic and management issues unique to the elderly population will be discussed broadly in this topic review.

Keywords: Parkinson's Disease (PD), diagnosis, management, elderly

SFP2024; 50(3): 35-39

INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide and the fastest growing one, with its prevalence more than doubling from 1990 to 2015.¹ Prevalence and incidence rates vary according to geographical regions, and are slightly lower in the East.² A local community-based study showed a prevalence rate of 61.9 per 100,000 for those above 50 years of age, age-adjusted to the 2000 WHO census. Rates increased exponentially with age, peaking in those aged 80 and above.³ With the rapidly ageing population in Singapore, PD prevalence will continue to increase, making it imperative for the family physician to be familiar with this condition. The disease presentation, trajectory, and management, with emphasis on issues specific to the older population, will be discussed.

PATHOPHYSIOLOGY, PHENOTYPES, AND PROGRESSION

PD is characterised pathologically by the presence of widespread cytoplasmic α -synuclein aggregation in the form of Lewy bodies, and neuronal loss in the ventrolateral substantia nigra. Recent evidence suggests that α -synuclein aggregates are propagated in a prion-like fashion, being released by affected neurons into the extracellular space and taken up by neighbouring neurons.⁴

The role of deranged intracellular homeostasis of α -synuclein in PD is supported by genetic studies that link mutations in LRRK2 and GBA (the most common genetic risk factor for PD) to reduced lysosomal autophagy system function. The final common pathway to cellular death may be mediated by mitochondrial dysfunction and oxidative stress.⁵

The loss of modulation of the substantia nigra pars compacta on the striatum, resulting in inhibition of the excitatory direct thalamo-cortico-basal ganglia pathways and facilitation of inhibitory indirect pathways, accounts for the motor symptoms of PD in a simplistic manner.

Clinical heterogeneity and lack of reliable biomarkers (for both diagnosis and prognosis) make it intuitive for clinicians studying PD to try and identify clinical phenotypes that help make sense of the disease course. Hoehn and Yahr observed in their seminal paper that "patients whose chief complaint is tremor have a slightly better prognosis than those whose akinesia or rigidity is the main manifestation". Categorisation of PD patients into "tremor-predominant" and "postural instability/gait disorder (PIGD; later referred to as "akinetic-rigid" in subsequent studies)" subtypes was first operationalised by Jankovic et al in the DATATOP study.⁶

Criticisms of this method of clinical subtyping include the arbitrary nature of the algorithms used to determine subtypes, resulting in patients being classified differently based on the algorithm used. A new method of determining clinical subtypes by using cluster analysis, a type of hypothesis-free analysis that removes the bias of choosing criteria based on experience, has gained popularity. A novel study applied non-motor symptoms including orthostatic hypotension, mild cognitive impairment, and rapid eye-movement sleep behaviour disorder to the algorithm and defined a new "diffuse/malignant" group of PD patients who had a rapid rate of progression.⁷ Whether these are distinct clinical variants of PD or simply different stages of the same disease process is still a matter of ongoing debate. The merit of these studies is to bring attention to the fact that all physicians should screen PD patients for both motor and non-motor symptoms to help anticipate disease course and manage potential complications.

Studies comparing early-onset or intermediate-onset PD to late-onset PD (LOPD) have demonstrated decreased, similar, and increased frequencies of tremor as presenting features in LOPD. Gait abnormalities were more common in LOPD but could have been confounded by existing comorbidities, which are more prevalent in older age groups.⁸ A cross-sectional study of middle-aged and old-aged PD patients showed that for a similar disease duration, patients with LOPD had greater motor impairment (higher bradykinesia and rigidity scores but not tremor scores). The

DR NEO XIUMIN SHERMYN

Associate Consultant

Department of Neurology, National Neuroscience Institute, Singapore

PROF TAN ENG KING

Senior Consultant

Department of Neurology, National Neuroscience Institute, Duke NUS Singapore

authors suggested that a more rapid disease progression or less aggressive medical treatment could account for this difference.⁹

DIAGNOSIS

The diagnosis of PD can be made in the presence of bradykinesia accompanied by one of two other cardinal motor features of rest tremor or rigidity. While bradykinesia can affect the voice, face, and gait, slowness of limb movements must be documented to establish a diagnosis of PD.¹⁰ The latest clinical criteria proposed by the International Parkinson and Movement Disorder Society (MDS) introduced non-motor supportive criteria for the first time, namely olfactory loss and cardiac sympathetic denervation. Importantly, autonomic dysfunction and dementia are no longer absolute exclusion criteria, supported by study findings of mild cognitive impairment and autonomic dysfunction in incident or incipient PD populations.^{11,12}

The accuracy of the clinical diagnosis of PD has not improved over the last 25 years despite advances made in the field of neuroimaging. A meta-analysis of clinic-pathologic studies showed a pooled diagnostic accuracy of 80.6 percent.¹³ While structural magnetic resonance imaging is helpful for differentiating PD and atypical Parkinsonism, demonstrating atrophy, iron deposition, and increased signal changes in particular brain regions in atypical Parkinsonism, these changes may not be apparent in early Parkinsonian presentation. Radionuclide imaging of presynaptic dopaminergic function shows a typical pattern of asymmetric tracer uptake in the posterior striatum but does not differentiate PD and atypical Parkinsonism. Metabolic imaging (e.g., with F-fluorodeoxyglucose¹⁸) might be useful but the lack of normative values and availability of techniques at most centres limit their potential.

The incidence rates of PD have been reported in several studies to decline in the eighth decade of life – this is at odds with the widely-accepted understanding of age as a risk factor of disease and may be due to under-diagnosis in this age group. Common musculoskeletal and neurological comorbidities in older patients contribute to tone, dexterity, and balance difficulties that are challenging to distinguish from the motor features of PD. In addition, patients and their families often mistake early signs and symptoms of PD for normal ageing.¹⁴

Conversely, while the clinical picture of PD has expanded vastly to include various non-motor features, it behoves the physician to exclude other possible aetiologies for each symptom. A good example would be constipation, for which an endoscopic evaluation to rule out malignancy may be appropriate before attribution to PD.

MANAGEMENT

PD affects multiple domains including motor, autonomic, psychological, and cognitive functions.¹⁵ The main aim of pharmacological therapy in PD is symptom control. As age has been found to be an independent risk factor for falls, cognitive impairment, and visual hallucinations, this review will focus on the management of these conditions.

Management of Motor Symptoms Including Falls

It is common clinical practice to start older patients on levodopa monotherapy for fear of an increased risk of adverse effects with a levodopa-sparing strategy.^{9,16} This fear is not unfounded as many older patients have comorbidities that require polypharmacy – increasing the risk of drug interactions – and themselves may lower the threshold for side effects of anti-Parkinsonian drugs (e.g., psychosis in a patient with pre-existing dementia or orthostatic hypotension in a patient with diabetic autonomic dysfunction). In addition, there are fewer concerns about levodopa-related motor complications like dyskinesia and fluctuations since these are more common in patients with a younger age of onset and longer disease duration.¹⁷

Gait and balance difficulties in PD increase with age. Falls in the elderly can lead to serious injuries, decreased mobility, and loss of independence. They are also substantially costly.¹⁸ The best predictor of a fall is history of a prior one. A comprehensive assessment to identify modifiable factors like orthostatic hypotension, presence of environmental hazards, and wearing off of dopaminergic drug effects is important. Cueing strategies and assistive devices are mainstay therapies in fall prevention. In view of the findings of cholinergic neuronal loss in the pedunculopontine nucleus of PD patients with gait instability, cholinesterase inhibitors have been evaluated for falls reduction, with the latest MDS update on treatments for motor symptoms of PD concluding that rivastigmine is possibly useful.¹⁹

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS: COGNITIVE IMPAIRMENT AND PSYCHOSIS

The gamut of neuropsychiatric symptoms in PD includes apathy, depression, anxiety, impulse control disorders, psychosis, and dementia. This review focuses on cognitive impairment and psychosis, for which incidence rates increase with age and disease duration.^{11,20}

The MDS diagnostic criteria for mild cognitive impairment (PD-MCI) allows for the cognitive decline to be reported by the patient, informant, or observed by the clinician. Cognitive deficits must be demonstrated on testing and should not interfere significantly with functional independence. The preferred test for global cognition in PD is the Montreal Cognitive Assessment (MoCA). PD-MCI can be further subtyped into single domain and multiple domain involvement, via comprehensive neuropsychological testing that includes at least two tests for each of the five

cognitive domains (attention and working memory, executive function, language, memory, and visuospatial function).²¹

The five-year prevalence of PD-MCI in an incident PD cohort has been reported to be >40 percent, with annual progression rates to dementia of 12.1 percent in patients with baseline PD-MCI.¹¹ It is important for physicians to screen PD patients regularly for cognitive impairment. PD with dementia may be difficult to distinguish from dementia with Lewy bodies (DLB) or Alzheimer's dementia because of the overlap of clinical and pathological changes. Significantly, the revised MDS diagnostic criteria qualifies that PD can be diagnosed regardless of when dementia occurs in relation to Parkinsonism onset, and in cases where Parkinsonism subsequently develops in a patient with dementia, the diagnosis "PD (DLB subtype)" is recommended.

Rivastigmine, a cholinesterase inhibitor, is clinically useful for the treatment of dementia in PD while donepezil and galantamine are possibly useful, in the MDS-commissioned update on treatment for non-motor symptoms of PD. There is insufficient evidence to support the use of cholinesterase inhibitors for non-dementia cognitive impairment.²²

Psychosis in PD tends to develop later in the disease course, arising in the context of clear sensorium. Insight is usually retained but may be lost with progression. Visual hallucinations of people or animals, lasting from seconds to minutes, usually occur in the evenings when lighting is low. Auditory hallucinations, if they occur, tend to accompany visual hallucinations, and – compared to those in primary psychotic disorders – are less likely to be of a threatening nature. Presence and passage hallucinations described respectively as the sense of a presence in the room, behind or beside the patient and the sense of movement in the periphery, may be a prodromal symptom and is not usually reported by patients. Delusion commonly takes the form of suspicions of spousal infidelity.²⁰

Management starts with identifying and treating reversible factors like concomitant infections, electrolyte abnormalities, cerebrovascular events, etc. The next step involves simplification of anti-Parkinsonian drug regimens with the gradual removal of drugs in the preferred order of anticholinergics, selegiline, amantadine, dopamine agonists, catechol-O-methyltransferase inhibitors, and levodopa.

Clozapine is clinically useful for the treatment of psychosis but can only be prescribed by a psychiatrist in our local context and required specialised monitoring. Quetiapine is hence the preferred anti-psychotic, but its use in demented person needs to be accompanied by a warning that there may be an increased risk of cardiovascular events and death. Pimavanserin, a selective serotonin 5-HT_{2A} agonist, is useful for the short-term treatment of PD psychosis.²²

MANAGEMENT OF AUTONOMIC DYSFUNCTION: ORTHOSTATIC HYPOTENSION

Orthostatic hypotension (OH) occurs in approximately 20 percent of those aged 65 and above, contributed, undoubtedly, by the presence of polypharmacy. This prevalence is even higher in PD patients, with rates of 30-50 percent, increasing with age and disease duration. Neurogenic hypotension occurs in Lewy-body disorders due to postganglionic sympathetic dysfunction, which results in cardiac denervation and impaired compensatory vasoconstriction upon standing.²³ Like cognitive impairment, OH significantly lowers quality of life (QoL) in PD patients and can occur early in disease.

The symptoms of OH, including tiredness and neck and shoulder discomfort (coat hanger pain), can be non-specific and easily missed. In one study, only 16 percent of PD patients with OH were symptomatic. Importantly, regardless of symptoms, OH was associated with greater healthcare utilisation and falls.²⁴

The management of OH is complicated by the frequent coexistence of supine hypertension. Espay et al argue for the prioritisation of OH over supine hypertension as OH poses risks for falls and cognitive impairment in the near or immediate future while the purported risks of cardiovascular events with supine hypertension occur over decades.²⁵ The authors propose that the American Geriatrics Society recommendation to accept supine hypertension in elderly (>80 years) patients without PD might also be appropriate for younger PD patients with coexistent OH and supine hypertension.

Nonpharmacological methods are attempted first. These include increasing water intake (often challenging for PD patients who have impaired gastric motility, urinary urgency, and decreased mobility), using physical counter-maneuvres (e.g., leg crossing, squatting), sleeping with head of bed elevated, avoiding autonomic stressors (e.g., large meals, hot showers), and using abdominal binders or compression stockings.

Possibly useful pharmacotherapy for OH are fludrocortisone (often prescribed with potassium supplement), midodrine, and droxidopa. Pyridostigmine, although not in the MDS guideline, is sometimes used with the potential additional benefit of improving constipation.

LIVING LIFE SUCCESSFULLY WITH PARKINSON'S DISEASE

The adage that "it takes a village to raise a child" may also be applied to the elderly PD patient, given the complexity of care. Given the sobering finding that PD patients have worse health-related QoL than patients with other chronic illnesses such as strokes, arthritis, diabetes, heart failure, and coronary heart disease, there is no doubt that PD care has to improve.²⁶ Helping our PD patients live life successfully starts by understanding their perception of success and

supporting the development of positive mindsets and acceptance of challenges, while at the same time drawing on family support.²⁷ Patient-centred care may sound cliché but cannot be further emphasised – patients need to agree upon set goals of management before a fruitful therapeutic alliance is established. A crucial member of the “village” is the caregiver whose burden and strain, if not addressed, may inadvertently result in poorer patient outcomes and institutionalisation in the long run. Other aspects of care include access to specialised allied healthcare, regular physical activity, support groups, and palliative care.²⁶

CONCLUSION

PD is a multifaceted disease with often overlooked non-motor symptoms that arguably impact QoL more substantially than motor symptoms. As our population ages, the general practitioner will increasingly encounter older PD patients in the community. Differences in illness presentation, response to medications, and presence of comorbidities serve as unique challenges to management in this patient group but can be overcome by a nuanced and careful approach.

REFERENCES

1. Dorsey ER, Bloem BR. The Parkinson Pandemic-A Call to Action. *JAMA Neurol.* 2018 Jan 1;75(1):9-10. doi: 10.1001/jamaneurol.2017.3299. PMID: 29131880.
2. Abbas MM, Xu Z, Tan LC. Epidemiology of Parkinson's Disease-East Versus West. *Mov Disord Clin Pract.* 2017 Dec 22;5(1):14-28. doi: 10.1002/mdc3.12568. PMID: 30363342; PMCID: PMC6174379.
3. Tan LC, Venketasubramanian N, Hong CY, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. *Neurology.* 2004 Jun 8;62(11):1999-2004. doi: 10.1212/01.wnl.0000128090.79756.10. PMID: 15184604.
4. Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? *Lancet Neurol.* 2010 Nov;9(11):1128-38. doi: 10.1016/S1474-4422(10)70213-1. Epub 2010 Sep 16. PMID: 20846907.
5. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nat Rev Dis Primers.* 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. PMID: 28332488.
6. von Coelln R, Shulman LM. Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. *Curr Opin Neurol.* 2016 Dec;29(6):727-734. doi: 10.1097/WCO.0000000000000384. PMID: 27749396.
7. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. *JAMA Neurol.* 2015 Aug;72(8):863-73. doi: 10.1001/jamaneurol.2015.0703. PMID: 26076039.
8. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson's disease. *Eur J Neurol.* 2009 Apr;16(4):450-6. doi: 10.1111/j.1468-1331.2008.02514.x. PMID: 19187262.
9. Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. *Arch Neurol.* 2003 Apr;60(4):529-33. doi: 10.1001/archneur.60.4.529. PMID: 12707066.
10. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Movement Disorders.* 2015 Oct;30(12):1591-601. *Mov Disord.* 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. PMID: 26474316.
11. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. *Neurology.* 2017 Feb 21; 88(8): 767-774. doi: 10.1212/WNL.0000000000003634. Epub 2017 Jan 20. PMID: 28108638.
12. Liepelt-Scarfone I, Pilotto A, Müller K, et al. Autonomic dysfunction in subjects at high risk for Parkinson's disease. *J Neurol.* 2015 Dec;262(12):2643-52. doi: 10.1007/s00415-015-7888-z. Epub 2015 Nov 3. PMID: 26530505.
13. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. *Neurology.* 2016 Feb 9; 86(6):566-76. doi: 10.1212/WNL.0000000000002350. Epub 2016 Jan 13. PMID: 26764028.
14. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. *Mov Disord.* 2000 Sep;15(5):819-25. doi: 10.1002/1531-8257(200009)15:5<819::aid-mds1009>3.0.co;2-p. PMID: 11009185.
15. Lauretani F, Maggio M, Silvestrini C, Nardelli A, Saccavini M, Ceda GP. Parkinson's disease (PD) in the elderly: an example of geriatric syndrome (GS)? *Arch Gerontol Geriatr.* 2012 Jan-Feb;54(1):242-6. doi: 10.1016/j.archger.2011.03.002. Epub 2011 Apr 2. PMID: 21459464.
16. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. *Mov Disord.* 2000 Jul;15(4):664-8. doi: 10.1002/1531-8257(200007)15:4<664::aid-mds1010>3.0.co;2-d. PMID: 10928576.
17. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. *Brain.* 2007 Jun 24; 130(8):2123-8. doi: 10.1093/brain/awm142. Epub 2007 Jun 24. PMID: 17586867.
18. Florence CS, Bergen G, Atherly A, Burns E, Stevens J, Drake C. Medical Costs of Fatal and Nonfatal Falls in Older Adults. *J Am Geriatr Soc.* 2018 Apr;66(4):693-698. doi: 10.1111/jgs.15304. Epub 2018 Mar 7. PMID: 29512120; PMCID: PMC6089380.
19. Fox SH, Katzschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord.* 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Erratum in: *Mov Disord.* 2018 Dec;33(12):1992. PMID: 29570866.
20. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease. *Drugs Aging.* 2008;25(8):665-82. doi: 10.2165/00002512-200825080-00004. PMID: 18665659; PMCID: PMC3045853.
21. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Mov Disord.* 2012 Mar;27(3):349-56. doi: 10.1002/mds.24893. Epub 2012 Jan 24. PMID: 22275317; PMCID: PMC3641655.
22. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. *Mov Disord.* 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: *Mov Disord.* 2019 May;34(5):765. PMID: 30653247; PMCID: PMC6916382.
23. Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. *Mov Disord.* 2018 Mar;33(3):372-390. doi: 10.1002/mds.27344. PMID: 29508455; PMCID: PMC5844369.
24. Merola A, Romagnolo A, Rosso M, et al. Autonomic dysfunction in Parkinson's disease: A prospective cohort study. *Mov Disord.* 2018 Mar;33(3):391-397. doi: 10.1002/mds.27268. Epub 2017 Dec 26. PMID: 29278286.
25. Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. *Lancet Neurol.* 2016 Aug; 15(9):954-966. doi: 10.1016/S1474-4422(16)30079-5. PMID: 27478953.

26. Lim SY, Tan AH, Fox SH, Evans AH, Low SC. Integrating Patient Concerns into Parkinson's Disease Management. *Curr Neurol Neurosci Rep.* 2017 Jan;17(1):3. doi: 10.1007/s11910-017-0717-2. PMID: 28102483.
27. Kang MY, Ellis-Hill C. How do people live life successfully with Parkinson's disease?. *J Clin Nurs.* 2015 Aug;24(15-16):2314-22. doi: 10.1111/jocn.12819. Epub 2015 May 4. PMID: 25939827.

LEARNING POINTS

- **Diagnosis of PD in the elderly is complicated by the presence of multiple age-related co-morbidities that may confound the clinical picture. Certain examination findings like the presence of a rest tremor or a supporting history of non-motor features (e.g., hyposmia, RBD) might be helpful in differentiating PD from these other co-morbidities.**
 - **Cognitive impairment and autonomic dysfunction may be present from the onset of motor symptoms in PD and should be sought for specifically by the physician during each consult, as these non-motor symptoms often negatively impact QoL and health outcomes.**
 - **The management of falls, cognitive impairment, psychosis, and orthostatic hypotension (often markers of advanced disease) has to be a well-considered and coordinated approach consisting largely of non-pharmacological interventions – crucially, allied healthcare input – and a small amount of pharmacological therapy.**
-